Mol-Gyn Logo

Laboratory for Molecular Gynecology
Head: Prof. Dr. rer. nat. Carsten Gründker
Dept. Gynecology and Obstetrics
Chairman: Prof. Dr. med. Günter Emons

UMG Logo




Mol-Gyn Lab






Central Units

Dept. Gynecology

Univ. Medical Center








Last Modification:




PD Dr. rer. nat. Rainer Girgert


Phone office: +49-(0)551-39 66512
Phone lab: +49-(0)551-39 22749

G-protein coupled receptor 30 (GPR30 / GPER) as therapeutic target for triple-negative breast cancers.

Deutsche Forschungsgemeinschaft


  • Bruchelt G, Buck J, Girgert R, Treuner J, Niethammer D. The role of reactive oxygen compounds derived from 6-hydroxydopamine for bone marrow purging from neuroblastoma cells. Biochem Biophys Res Commun. 1985 Jul 16;130(1):168-74.

  • Buck J, Bruchelt G, Girgert R, Treuner J, Niethammer D. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res. 1985 Dec;45(12 Pt 1):6366-70.

  • Treuner J, Klingebiel T, Feine U, Buck J, Bruchelt G, Dopfer R, Girgert R, Müller-Schauenburg W, Meinke J, Kaiser W, et al. Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Pediatr Hematol Oncol. 1986;3(3):205-16.

  • Bruchelt G, Girgert R, Buck J, Wolburg H, Niethammer D, Treuner J. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res. 1988 Jun 1;48(11):2993-7.

  • Girgert R, Marini P, Janessa A, Bruchelt G, Treuner J, Schweizer P. Inhibition of the membrane localization of p21 ras proteins by lovastatin in tumor cells possessing a mutated N-ras gene. Oncology. 1994 Jul-Aug;51(4):320-2.

  • Girgert R, Schweizer P, Bock I, Narr R, Bruchelt G. Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells. J Cancer Res Clin Oncol. 1995;121(5):262-6.

  • Girgert R, Treuner J, Schweizer P. [Molecular biology markers of neuroblastoma as the basis for a therapy concept]. Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1053-5.

  • Girgert R, Schweizer P. Regulation of expression of two different transcripts of the NF-1 gene in neuroblastoma. J Neurooncol. 1997 Jan;31(1-2):93-7.

  • Lenz M, Miehe WP, Vahrenwald F, Bruchelt G, Schweizer P, Girgert R. Cholesterol based antineoplastic strategies. Anticancer Res. 1997 Mar-Apr;17(2A):1143-6.

  • Vahrenwald F, Galka K, Jürgens G, Bruchelt G, Girgert R, Schweizer P. Toxic reactions of oxidized LDL on cells of acute myeloid leukemia. Leuk Res. 1997 Nov-Dec;21(11-12):1071-6.

  • Schwäble J, Wittrock J, Schweizer P, Girgert R. Detection of rare target genes on northern blots with cDNA probes labeled by reverse transcriptase-polymerase chain reaction with simultaneous digoxigenin incorporation. Anal Biochem. 1998 Aug 15;262(1):77-9.

  • Girgert R, Vogt Y, Becke D, Bruchelt G, Schweizer P. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. Cancer Lett. 1999 Apr 1;137(2):167-72.

  • Barthlen W, Schäfer J, Girgert R, Schuster M, Schweizer P. Apoptosis of cultured neuroblastoma cells is induced by ceramide and not by ligation of the Fas/Apo-1/CD95 receptor. Chemotherapy. 1999 Jul-Aug;45(4):258-67.

  • Girgert R, Hohnecker A, Wittrock J, Schweizer P. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate. Anticancer Res. 1999 Jul-Aug;19(4B):2959-62.

  • Marini P, MacLeod RA, Treuner C, Bruchelt G, Böhm W, Wolburg H, Schweizer P, Girgert R. SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation. Cancer Genet Cytogenet. 1999 Jul 15;112(2):161-4.

  • Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, Treuner J, Liu C, Niethammer D, Beck JF. Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep. 1999 Sep-Oct;6(5):1143-6.

  • Girgert R, Schweizer P, Schwäble J. Neuroblastoma: induction of differentiation (Part I). Basical science in pediatric surgery. Eur J Pediatr Surg. 2000 Apr;10(2):79-82.

  • Girgert R, Wittrock J, Schweizer P. Neuroblastoma: inhibition of progression (Part II). Basic science in pediatric surgery. Eur J Pediatr Surg. 2001 Dec;11(6):363-7.

  • Wittrock J, Schweizer P, Girgert R. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Anticancer Res. 2002 Nov-Dec;22(6C):4205-9.

  • Girgert R, Wittrock J, Pfister S, Schweizer P. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF. J Cancer Res Clin Oncol. 2003 Apr;129(4):227-33.

  • Barthlen W, Flaadt D, Girgert R, Conzelmann J, Schweizer P, Zugmaier G, Buck M, Knabbe C. Significance of heparin-binding growth factor expression on cells of solid pediatric tumors. J Pediatr Surg. 2003 Sep;38(9):1296-304.

  • Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V. Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. Neuro Endocrinol Lett. 2003 Dec;24(6):440-4.

  • Girgert R, Schimming H, Körner W, Gründker C, Hanf V. Induction of tamoxifen resistance in breast cancer cells by ELF electromagnetic fields. Biochem Biophys Res Commun. 2005 Nov 4;336(4):1144-9.

  • Girgert R, Gründker C, Emons G, Hanf V. Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells. Bioelectromagnetics. 2008 Apr;29(3):169-76.

  • Girgert R, Emons G, Hanf V, Gründker C. Exposure of mcf-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator system. Int J Gynecol Cancer. 2009 Apr;19(3):334-8.

  • Girgert R, Hanf V, Emons G, Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. 2009 Aug;47(1):23-3

  • Girgert R, Hanf V, Emons G, Gründker C (2010) Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields. Bioelectromagnetics 31(3):237-245

  • Gross O, Girgert R, Beirowski B, Kretzler M, Kang HG, Kruegel J, Miosge N, Busse AC, Segerer S, Vogel WF, Müller GA, Weber M (2010) Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 29(5):346-356

  • Girgert R, Martin M, Kruegel J, Miosge N, Temme J, Eckes B, Müller GA, Gross O (2010) Integrin α2-deficient mice provide insights into specific functions of collagen receptors in the kidney. Fibrogenesis Tissue Repair 3:19

  • Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA (2011) Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 24(3):355-361

  • Girgert R, Emons G, Gründker C (2012) Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Research and Treatment 134:199-205

  • Rubel D, Stock J, Ciner A, Hiller H, Girgert R, Müller GA, Gross O (2014) Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. Nephrol Dial Transplant 29(5):1012-1019

  • Rubel D, Frese J, Martin M, Leibnitz A, Girgert R, Miosge N, Eckes B, Müller GA, Gross O (2014) Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Matrix Biol 34:13-21

  • Girgert R, Emons G, Gründker C (2014) Inhibition of GPR30 by estriol successfully prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol. BMC Cancer 14:935

  • Hinsche O, Girgert R, Emons G, Gründker C (2015) Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. International Journal of Oncology 46:878-884

  • Girgert R, Emons G, Gründker C (2017)  Gefitinib inhibits growth of triple-negative breast cancer cells in part by reduction of GPER expression, preventing 17β-estradiol induced cell growth. Oncology Reports 37(2):1212-1218